Status:
COMPLETED
Study of Immunotherapy to Treat Advanced Prostate Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Advanced prostate cancer
- At least 1 bone metastasis
- Testosterone \< 50 ng/dl
- Prior treatment with docetaxel
Exclusion
- Brain metastasis
- Autoimmune disease
- Known HIV, Hep B, or Hep C infection
- More than 2 prior systemic anticancer regimens for prostate cancer
- Prior treatment on BMS CA180227 for prostate cancer
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
988 Patients enrolled
Trial Details
Trial ID
NCT00861614
Start Date
May 1 2009
End Date
August 1 2015
Last Update
September 30 2016
Active Locations (158)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Cancer Center
Mobile, Alabama, United States, 36608
2
Alaska Clinical Research Center, Llc
Anchorage, Alaska, United States, 99508
3
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States, 85715
4
Highlands Oncology Group, P.A.
Fayetteville, Arkansas, United States, 72703